Methods of screening for a tumor or tumor progression to the metastatic state

• US 5,945,675 A
• Filed: 03/17/1997
• Issued: 08/31/1999
• Est. Priority Date: 03/18/1996
• Status: Expired due to Term

• Current Assignee: Donald C. Malins
• Original Assignee: Pacific Northwest Research Foundation
• Inventors: Malins, Donald C.
• Primary Examiner(s): Hannaher, Constantine
• Application Number:
  US08/819,144
• Time in Patent Office: 897 Days
• Field of Search: 250/339.08, 250/339.12
• US Class Current: 250/339.12
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: G01J 3/45 Interferometric spectrometry
• CPC Class Codes: G01N 2021/3595 using FTIR
• CPC Class Codes: G01N 21/35 using infrared light G01N21/39 takes precedence
• CPC Class Codes: G01N 2201/129 Using chemometrical methods
• CPC Class Codes: G16B 40/00 ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• CPC Class Codes: G16B 40/30 Unsupervised data analysis

Abstract

Methods of screening for a tumor or tumor progression to the metastatic state are a provided. The screening methods are based on the characterization of DNA by principal components analysis of spectral data yielded by Fourier transform-infrared spectroscopy of DNA samples. The methods are applicable to a wide variety of DNA samples and cancer types.

Claims

1. A method of screening for tumor progression to the metastatic state comprising the steps of:

(a) subjecting isolated DNA or isolated nuclei to Fourier transform-infrared (FT-IR) spectroscopy to produce FT-IR spectral data;

(b) analyzing the FT-IR spectral data of step (a) by principal components analysis (PCA); and

(c) comparing the PCA of step (b) to the PCA of FT-IR spectra for DNA samples from non-metastatic and metastatic tumor samples.

2. A method according to claim 1 wherein the tumor is breast, urogenital, melanoma, liver, renal, pancreatic, lung, blood related, brain or colorectal cancer.

3. A method according to claim 2 wherein the urogenital cancer is prostate, ovarian or endometrial cancer.

4. A method according to claim 2 wherein the urogenital cancer is prostate cancer.

5. A method according to claim 2 wherein the tumor is breast cancer.